Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

- Davies, Christina, Pan, Hongchao, Bradbury, Joan, Clarke, Michael, Collins, Rory, Davis, Susan R., Delmestri, Antonella, Forbes, John F., Haddad, Peiman, Hou, Ming-Feng, Inbar, Moshe, Khaled, Hussein, Godwin, Jon, Kielanowska, Joanna, Kwan, Wing-Hong, Mathew, Beela S., Mittra, Indraneel, Mueller, Bettina, Nicolucci, Antonio, Peralta, Octavio, Pernas, Fany, Petruzelka, Lubos, Pienkowski, Tadeusz, Gray, Richard, Radhika, Ramachandran, Rajan, Balakrishnan, Rubach, Maryan T., Tort, Sera, Urrutia, Gerard, Valentini, Miriam, Wang, Yaochen, Peto, Richard, Arriagada, Rodrigo, Raina, Vinod, Abraham, Mirta, Medeiros Alencar, Victor Hugo, Badran, Atef, Bonfill, Xavier

Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 Study

- Colleoni, Marco, Giobbie-Hurder, Anita, Chirgwin, Jacquie, Pienkowski, Tadeusz, Wardley, Andrew, Price, Karen N., Gelber, Richard D., Coates, Alan S., Goldhirsch, Aron, Regan, Meredith M., Thürlimann, Beat, Mouridsen, Henning, Mauriac, Louis, Forbes, John F., Paridaens, Robert, Láng, István, Smith, Ian